8 August 2017 - - The global CNS therapeutic market is expected to reach USD 128.9bn by 2025, according to a new report by US market research and consulting company Grand View Research, Inc.

A rising prevalence of mental illnesses and increasing awareness regarding psychiatric disorders are driving market growth.

In addition, expanding geriatric population and rising prevalence of lifestyle-associated CNS disorders are increasing global demand for CNS therapeutics.

Mental health segment accounted for the largest market share in 2016.

It is expected to retain its dominance over the forecast period owing to developing therapeutic options for mental diseases such as personality disorders and binge eating disorders.

This segment is followed by degenerative disorders segment. There is growing awareness regarding neurodegenerative diseases owing to increase in initiatives by government and nongovernment organizations, such as Alzheimer's and Related Disorders Society of India.

These organisations conduct awareness campaigns and conferences, such as Asia Pacific Conference of ADI at New Delhi and Kerala State Initiative on Dementia, which encourage the adoption of treatment for degenerative and mental disorders.

The cancer segment is expected to emerge as the fastest growing segment in the Central Nervous System therapeutics market. High demand for effective treatment and a large number of drugs in later phases of clinical trials are factors expected to propel the growth of the segment.

Global mental health therapeutics revenue accounted for 48% share in 2016 and is expected to grow at a significant rate from 2016 to 2025. Global demand for the treatment of Parkinson's and Alzheimer's diseases is anticipated to witness extensive growth over the next nine years.

The industry in Asia Pacific is expected to report fastest growth over the forecast period owing to various developments across major economies of the region, especially in the mental health sector.
Key players including Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.; Biogen, Inc.; Johnson and Johnson Services, Inc.; Eli Lilly and Co; and Novartis AG led the global CNS disease treatment market by capturing a majority share.